GP
EPRX

Guardian Partners’s Eupraxia Pharmaceuticals EPRX Stock Holding History

Guardian Partners’s Portfolio EPRX Stock Details EPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-24,130
Closed -$147K – 230
2025
Q3 		$147K Buy
+24,130
New +$131K 0.01% 179

Other funds holding EPRX

BGC
Beutel, Goodman & Co Toronto, Ontario, Canada $14.8B AUM 15.12% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
SC
Scotia Capital Toronto, Ontario, Canada $24.3B AUM 29.21% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $273M AUM
ABG
Ally Bridge Group New York $124M AUM 249.88% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return

Guardian Partners's EPRX Position: Q4 2025 in Review

Guardian Partners sold out of Eupraxia Pharmaceuticals (EPRX) in Q4 2025, closing a stake of 24,130 shares — an estimated $147K sold.

Guardian Partners first reported a position in EPRX in Q3 2025 and held it in 1 quarter. The position peaked at $147K in Q3 2025. 35 funds tracked by Wall St. Rank hold EPRX as of Q4 2025.

  • Guardian Partners reported no remaining Eupraxia Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Guardian Partners sold 24,130 Eupraxia Pharmaceuticals shares in Q4 2025, an estimated $147K.
  • Guardian Partners first reported a position in Eupraxia Pharmaceuticals in Q3 2025 and held it in 1 quarter.
  • Guardian Partners's Eupraxia Pharmaceuticals position peaked at $147K in Q3 2025.
  • 35 funds tracked by Wall St. Rank held Eupraxia Pharmaceuticals as of Q4 2025.

Based on Guardian Partners's 13F filing for Q4 2025, filed 17 Feb 2026.